218 related articles for article (PubMed ID: 16845661)
1. Combination of a rapamycin analog (CCI-779) and interferon-gamma is more effective than single agents in treating a mouse model of tuberous sclerosis complex.
Lee L; Sudentas P; Dabora SL
Genes Chromosomes Cancer; 2006 Oct; 45(10):933-44. PubMed ID: 16845661
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models.
Lee L; Sudentas P; Donohue B; Asrican K; Worku A; Walker V; Sun Y; Schmidt K; Albert MS; El-Hashemite N; Lader AS; Onda H; Zhang H; Kwiatkowski DJ; Dabora SL
Genes Chromosomes Cancer; 2005 Mar; 42(3):213-27. PubMed ID: 15578690
[TBL] [Abstract][Full Text] [Related]
3. Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779.
Messina MP; Rauktys A; Lee L; Dabora SL
BMC Pharmacol; 2007 Nov; 7():14. PubMed ID: 17986349
[TBL] [Abstract][Full Text] [Related]
4. Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models.
Lee N; Woodrum CL; Nobil AM; Rauktys AE; Messina MP; Dabora SL
BMC Pharmacol; 2009 Apr; 9():8. PubMed ID: 19368729
[TBL] [Abstract][Full Text] [Related]
5. Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways.
Kwiatkowski DJ; Manning BD
Hum Mol Genet; 2005 Oct; 14 Spec No. 2():R251-8. PubMed ID: 16244323
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in neurobiology of Tuberous Sclerosis Complex.
Napolioni V; Moavero R; Curatolo P
Brain Dev; 2009 Feb; 31(2):104-13. PubMed ID: 19028034
[TBL] [Abstract][Full Text] [Related]
7. Rapamycin as a therapy of choice after renal transplantation in a patient with tuberous sclerosis complex.
Tarasewicz A; Debska-Slizień A; Konopa J; Zdrojewski Z; Rutkowski B
Transplant Proc; 2009 Nov; 41(9):3677-82. PubMed ID: 19917366
[TBL] [Abstract][Full Text] [Related]
8. Effects of rapamycin in the Eker rat model of tuberous sclerosis complex.
Kenerson H; Dundon TA; Yeung RS
Pediatr Res; 2005 Jan; 57(1):67-75. PubMed ID: 15557109
[TBL] [Abstract][Full Text] [Related]
9. Perturbed IFN-gamma-Jak-signal transducers and activators of transcription signaling in tuberous sclerosis mouse models: synergistic effects of rapamycin-IFN-gamma treatment.
El-Hashemite N; Zhang H; Walker V; Hoffmeister KM; Kwiatkowski DJ
Cancer Res; 2004 May; 64(10):3436-43. PubMed ID: 15150095
[TBL] [Abstract][Full Text] [Related]
10. Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors.
Woodrum C; Nobil A; Dabora SL
J Transl Med; 2010 Feb; 8():14. PubMed ID: 20146790
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic targeting of mTOR in tuberous sclerosis.
Sampson JR
Biochem Soc Trans; 2009 Feb; 37(Pt 1):259-64. PubMed ID: 19143643
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model.
Mi R; Ma J; Zhang D; Li L; Zhang H
J Genet Genomics; 2009 Jun; 36(6):355-61. PubMed ID: 19539245
[TBL] [Abstract][Full Text] [Related]
13. Defects in cell polarity underlie TSC and ADPKD-associated cystogenesis.
Bonnet CS; Aldred M; von Ruhland C; Harris R; Sandford R; Cheadle JP
Hum Mol Genet; 2009 Jun; 18(12):2166-76. PubMed ID: 19321600
[TBL] [Abstract][Full Text] [Related]
14. Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis.
Franz DN
Expert Rev Anticancer Ther; 2011 Aug; 11(8):1181-92. PubMed ID: 21916571
[TBL] [Abstract][Full Text] [Related]
15. Tuberous sclerosis complex and epilepsy: recent developments and future challenges.
Holmes GL; Stafstrom CE;
Epilepsia; 2007 Apr; 48(4):617-30. PubMed ID: 17386056
[TBL] [Abstract][Full Text] [Related]
16. Behavioural and EEG effects of chronic rapamycin treatment in a mouse model of tuberous sclerosis complex.
Cambiaghi M; Cursi M; Magri L; Castoldi V; Comi G; Minicucci F; Galli R; Leocani L
Neuropharmacology; 2013 Apr; 67():1-7. PubMed ID: 23159330
[TBL] [Abstract][Full Text] [Related]
17. Loss of Tsc1 or Tsc2 induces vascular endothelial growth factor production through mammalian target of rapamycin.
El-Hashemite N; Walker V; Zhang H; Kwiatkowski DJ
Cancer Res; 2003 Sep; 63(17):5173-7. PubMed ID: 14500340
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy.
Geoerger B; Kerr K; Tang CB; Fung KM; Powell B; Sutton LN; Phillips PC; Janss AJ
Cancer Res; 2001 Feb; 61(4):1527-32. PubMed ID: 11245461
[TBL] [Abstract][Full Text] [Related]
19. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
MacKeigan JP; Krueger DA
Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
[TBL] [Abstract][Full Text] [Related]
20. A mouse model of tuberous sclerosis 1 showing background specific early post-natal mortality and metastatic renal cell carcinoma.
Wilson C; Idziaszczyk S; Parry L; Guy C; Griffiths DF; Lazda E; Bayne RA; Smith AJ; Sampson JR; Cheadle JP
Hum Mol Genet; 2005 Jul; 14(13):1839-50. PubMed ID: 15888477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]